



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/579,163	05/11/2006	Deok-Hoon Park	DE1683	3283
1109	7590	03/25/2010		
DAVID A. EINHORN BAKER & HOSTETLER, LLP 45 ROCKEFELLER PLAZA NEW YORK, NY 10111			EXAMINER KISHORE, GOLLAMUDI S	
			ART UNIT	PAPER NUMBER
			1612	
			NOTIFICATION DATE	DELIVERY MODE
			03/25/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

IPGNY@BAKERLAW.COM

DEINHORN@BAKERLAW.COM

DCIPDOCKETING@BAKERLAW.COM

Office Action Summary

Application No.

10/579,163

Applicant(s)

PARK ET AL.

Examiner

Gollamudi S. Kishore

Art Unit

1612

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-11 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-11 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SF 298)
Paper No(s)/Mail Date 2-17-10
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

Claims included in the prosecution are 1-11.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 3-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 3 (a) recites, "dissolving oil-phase components-----". It is unclear as to what the oil phase components dissolved in. 'ceramides' is misspelled.

The meets and bounds of 'synthetic compounds' in claim 10 is unclear. Proteins, peptides and others recited in the claim can be synthetic.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Popp (US 2006/0029657) in combination with Foldvari (5,853,755).

Popp discloses topical skin protectant compositions containing 0.05 to 5 % phospholipid (hydrogenated lecithin), 0.001 to about 1.5 % ceramide, 0.1 to 5 % squalane, 8 to 30 % triglyceride, 2 to 5 % phytosterol. Although Popp teaches the use of

an essential fatty acid, the fatty acid is in the form of an oil. The composition is prepared by heating the oil phase components at a temperature of 40-50 degrees, mixing with the aqueous phase at the same temperature and homogenizing the mixture at 3000 rpm (0030-0117; 0164; 0195-0210; examples and claims.). Since the method of preparation is the same, the presence of multilayered liposomes is implicit. What is lacking in Popp is the use of fatty acid as such.

Foldvari teaches multilamellar vesicles for topical delivery. The liposomes contain a phospholipid, a ceramide and fatty substances to enhance the strength of the lipid bilayers. These include cholesterol and fatty acids such as stearic acid (0.5 %). The compositions further include oil and an active agent. The hydrophilic solvents include ethanol. The method of preparation involves mixing the two phases together at 40 to 80 degrees and homogenizing the mixture (abstract, col. 4, lines 8-41; col. 5, line 1 through col. 7, line 3; col. 8, line 47 through col. 10, line 9; col. 11, line 1 through col. 12, line 35; Examples). What is lacking Foldvari is the inclusion of squalane.

To include a fatty acid in the compositions of Popp would have been obvious to one of ordinary skill in the art since Foldvari teaches that fatty acids enhance the strength of the lipid bilayers. Alternately, to include squalane in the compositions of Foldvari would have been obvious to one of ordinary skill in the art with a reasonable expectation of success since Popp teaches that squalane is a therapeutic ingredient for the skin and its routine incorporation in topical formulations.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S. Kishore whose telephone number is (571)

272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Krass Frederick can be reached on (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gollamudi S Kishore/
Primary Examiner, Art Unit 1612

GSK